These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3180536)

  • 1. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia.
    Bijlsma JW; Raymakers JA; Mosch C; Hoekstra A; Derksen RH; Baart de la Faille H; Duursma SA
    Clin Exp Rheumatol; 1988; 6(2):113-9. PubMed ID: 3180536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
    Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
    J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glucocorticoid-induced osteopenia].
    Glerup H; Eriksen EF; Mosekilde L
    Ugeskr Laeger; 1994 Sep; 156(38):5489-94. PubMed ID: 7941080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
    Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deflazacort versus prednisone in patients with giant cell arteritis: effects on bone mass loss.
    Cacoub P; Chemlal K; Khalifa P; Wechsler B; De Gennes C; Belmatoug N; Cohen P; Ziza JM; Verdoncq B; Piette JC
    J Rheumatol; 2001 Nov; 28(11):2474-9. PubMed ID: 11708421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineral loss in cortical and trabecular bone during high-dose prednisone treatment.
    Rickers H; Deding A; Christiansen C; Rødbro P
    Calcif Tissue Int; 1984 May; 36(3):269-73. PubMed ID: 6432291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis.
    Floreani A; Carderi I; Ferrara F; Rizzotto ER; Luisetto G; Camozzi V; Baldo V
    Dig Liver Dis; 2007 Jun; 39(6):544-8. PubMed ID: 17416215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a computerized order set to increase prescription of calcium and vitamin D supplementation in patients receiving glucocorticoids.
    Kohler MJ; Amezaga M; Drozd J; Crowley ST; Gulanski B; Anderson DR; Fraenkel L
    J Gen Intern Med; 2013 Jun; 28(6):825-9. PubMed ID: 23404201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.
    McKeown E; Bykerk VP; De Leon F; Bonner A; Thorne C; Hitchon CA; Boire G; Haraoui B; Ferland DS; Keystone EC; Pope JE;
    Rheumatology (Oxford); 2012 Sep; 51(9):1662-9. PubMed ID: 22539481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of glucocorticoid-induced osteopenia: effect of oral 25-hydroxyvitamin D and calcium.
    Di Munno O; Beghe F; Favini P; Di Giuseppe P; Pontrandolfo A; Occhipinti G; Pasero G
    Clin Rheumatol; 1989 Jun; 8(2):202-7. PubMed ID: 2758767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimizing calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction.
    Yendt ER; Kovacs KA; Jones G
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):855-63. PubMed ID: 18419790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dynamics of bone biochemical markers in nephrotic children treated with prednisone and metabolites of vitamin D].
    Wojnar J; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
    Przegl Lek; 2007; 64(9):552-8. PubMed ID: 18510075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of anticonvulsant drug-induced bone disease.
    Drezner MK
    Epilepsy Behav; 2004 Feb; 5 Suppl 2():S41-7. PubMed ID: 15123011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of 1 alpha(OH)-vitamin D3 and 24,25(OH)2-vitamin D3 on long bones of glucocorticoid-treated rats.
    Turnquist J; Ornoy A; Eini D; Schwartz Z
    Acta Anat (Basel); 1992; 145(1):61-7. PubMed ID: 1414214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA; Bravenboer N; Witte BI; Dijkstra G; van der Woude CJ; Stokkers PC; Russel MG; Oldenburg B; Pierik M; Roos JC; van Hogezand RA; Dik VK; Oostlander AE; Netelenbos JC; van de Langerijt L; Hommes DW; Lips P;
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.